Should You Be Concerned About Imprimis Pharmaceuticals Incs Shareholders
Macroaxis does not monitor all media channels or aggregates social signals for Imprimis Pharmaceuticals. But even though we do not provide professional-grade financial sentiment analysis on Imprimis Pharmaceuticals, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Imprimis Pharmaceuticals. Please also check Imprimis Pharmaceuticals Hype Analysis, Imprimis Pharmaceuticals Correlation and Imprimis Pharmaceuticals Performance.
Simply Wall StFull coverage
|This media report from simplywall.st distributed on March 8, 2018 was a factor to the next trading day price decrease.The trading delta at closing time against the next closing price was 5.24% . The trading delta at closing time when the story was published against the current closing price is 183.33% .|
Similar stores for Imprimis Pharmaceuticals
Imprimis Pharmaceuticals Inc on Focus After Report of Less Shorts The Cardinal WeeklyInvestors sentiment increased to 6.5 in 2018 Q3. Its up 4.70, from 1.8 in 2018Q2. It improved, as 0 investors sold Imprimis Pharmaceuticals, Inc. shares while.
Imprimis Pharmaceuticals, Inc. closed at 6.11 on Wednesday with moved of 2.69 percent While West Pharmaceutical Services, Inc. closed at 107.75, 1 year low of 30.23 percent and a 1 year high of -13.86 Stock Market FloorImprimis Pharmaceuticals, Inc. s closed at 6.11 with move of 2.69 percent on Wednesday. Investors of this company earned a return of -25.20 percent on the assets ...
Imprimis Pharmaceuticals Inc Stock Institutional Investors Feel Good About Thorold NewsImprimis Pharmaceuticals Inc institutional sentiment increased to 1.8 in 2018 Q2. Its up 0.92, from 0.88 in 2018Q1. The ratio is better, as 9 ...
Imprimis Pharmaceuticals Inc Big Money 2018 Q2 Sentiment at 1.8 The EN BulletinIn Q2 2018 Imprimis Pharmaceuticals Inc big money sentiment increased to 1.8, according to SEC filings. So its up 0.92, from 2018Q1s 0.88.
Nasdaq Click Insider Selling Imprimis Pharmaceuticals Inc Director Sells 10000 Shares of Stock Fairfield CurrentWhich Market Offer More Value iStar Inc. , Imprimis Pharmaceuticals, Inc. StockNewsGazetteFull coverage
Marea Informative Full coverage
Seeking AlphaImprimis Pharmaceuticals Announces Third Quarter 2018 Results NasdaqFull coverage
Analyst JournalFull coverage
Nasdaq Click Full coverage
Filed transaction by Imprimis Pharmaceuticals director. General open market or private sale of non-derivative or derivative security
Florida Recorder Full coverage
Herald KSFull coverage
Shares Owned by Institutions